Zevra Therapeutics Stock Buy Hold or Sell Recommendation
| ZVRA Stock | 8.21 0.20 2.50% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Zevra Therapeutics is 'Strong Sell'. Macroaxis provides Zevra Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZVRA positions.
Check out Zevra Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide. In addition, we conduct extensive research on individual companies such as Zevra and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Zevra |
Execute Zevra Therapeutics Buy or Sell Advice
The Zevra recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zevra Therapeutics. Macroaxis does not own or have any residual interests in Zevra Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zevra Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Zevra Therapeutics Trading Alerts and Improvement Suggestions
| Zevra Therapeutics generated a negative expected return over the last 90 days | |
| Zevra Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 23.61 M. Net Loss for the year was (105.51 M) with profit before overhead, payroll, taxes, and interest of 16.2 M. | |
| Zevra Therapeutics generates negative cash flow from operations | |
| About 63.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView |
Zevra Therapeutics Returns Distribution Density
The distribution of Zevra Therapeutics' historical returns is an attempt to chart the uncertainty of Zevra Therapeutics' future price movements. The chart of the probability distribution of Zevra Therapeutics daily returns describes the distribution of returns around its average expected value. We use Zevra Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zevra Therapeutics returns is essential to provide solid investment advice for Zevra Therapeutics.
| Mean Return | -0.0052 |
| Value At Risk | -4.47 |
| Potential Upside | 4.66 |
| Standard Deviation | 2.72 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zevra Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Zevra Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 767K | 108.0M | (46.9M) | (22.4M) | (9.3M) | (8.8M) | |
| Free Cash Flow | (2.0M) | 10.3M | (18.8M) | (33.8M) | (69.7M) | (66.2M) | |
| Depreciation | 273K | 257K | 944K | 1.0M | 6.4M | 6.7M | |
| Other Non Cash Items | 7.2M | 460K | 18.1M | 5.6M | 14.6M | 15.3M | |
| Capital Expenditures | 26K | 33K | 102K | 93K | 296K | 0.0 | |
| Net Income | (12.8M) | (8.6M) | (41.5M) | (46.0M) | (105.5M) | (100.2M) | |
| End Period Cash Flow | 4.3M | 112.3M | 65.5M | 43.0M | 33.8M | 30.2M | |
| Investments | (33K) | (15.5M) | (36.7M) | (28.0M) | (22.2M) | (23.3M) |
Zevra Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zevra Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zevra Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zevra stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 0.22 | |
σ | Overall volatility | 2.81 | |
Ir | Information ratio | -0.0066 |
Zevra Therapeutics Volatility Alert
Zevra Therapeutics exhibits very low volatility with skewness of -0.09 and kurtosis of 0.66. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Zevra Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Zevra Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Zevra Therapeutics Fundamentals Vs Peers
Comparing Zevra Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zevra Therapeutics' direct or indirect competition across all of the common fundamentals between Zevra Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zevra Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zevra Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Zevra Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Zevra Therapeutics to competition |
| Fundamentals | Zevra Therapeutics | Peer Average |
| Return On Equity | -2.08 | -0.31 |
| Return On Asset | -0.31 | -0.14 |
| Operating Margin | (1.28) % | (5.51) % |
| Current Valuation | 435.09 M | 16.62 B |
| Shares Outstanding | 54.12 M | 571.82 M |
| Shares Owned By Insiders | 6.85 % | 10.09 % |
| Shares Owned By Institutions | 62.98 % | 39.21 % |
| Number Of Shares Shorted | 5.78 M | 4.71 M |
| Price To Book | 11.20 X | 9.51 X |
| Price To Sales | 18.82 X | 11.42 X |
| Revenue | 23.61 M | 9.43 B |
| Gross Profit | 16.2 M | 27.38 B |
| EBITDA | (76.4 M) | 3.9 B |
| Net Income | (105.51 M) | 570.98 M |
| Total Debt | 60.3 M | 5.32 B |
| Book Value Per Share | 0.74 X | 1.93 K |
| Cash Flow From Operations | (69.67 M) | 971.22 M |
| Short Ratio | 14.60 X | 4.00 X |
| Earnings Per Share | (2.28) X | 3.12 X |
| Price To Earnings To Growth | 10.67 X | 4.89 X |
| Target Price | 21.63 | |
| Number Of Employees | 59 | 18.84 K |
| Beta | 1.98 | -0.15 |
| Market Capitalization | 444.29 M | 19.03 B |
| Total Asset | 178.13 M | 29.47 B |
| Retained Earnings | (505.29 M) | 9.33 B |
| Working Capital | 51.96 M | 1.48 B |
| Net Asset | 178.13 M |
Note: Disposition of 61273 shares by Neil McFarlane of Zevra Therapeutics at 7.8571 subject to Rule 16b-3 [view details]
Zevra Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zevra . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Zevra Therapeutics Buy or Sell Advice
When is the right time to buy or sell Zevra Therapeutics? Buying financial instruments such as Zevra Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Zevra Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Zevra Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.